Status:

COMPLETED

Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)

Lead Sponsor:

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Conditions:

Coronary Atherosclerosis

Coronary Artery Calcification

Eligibility:

MALE

35-84 years

Phase:

PHASE3

Brief Summary

1. Statement of Problem According to the National Fire Protection Association (NFPA), 43.7% of all firefighters that died on the job experienced sudden cardiac death. The job also affords an incre...

Detailed Description

Inclusion Criteria * Calcium scan with Agatston score \>20 * Age 35-84 years * Subjects must provide written informed consent after the scope and nature of the investigation has been explained to the...

Eligibility Criteria

Inclusion

  • Calcium scan with Agatston score \>20
  • Age 35-84 years
  • Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
  • Subjects should be stable on their concomitant medications for at least 12 weeks prior to randomization
  • Subjects who agree to refrain from supplemental garlic or significant dietary garlic

Exclusion

  • A contraindication to Aged Garlic Extract therapy including: known hypersensitivity to drug.
  • Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
  • Weight in excess of 325 pounds
  • Bleeding disorder
  • History of myocardial infarction, stroke or life-threatening arrhythmia within the prior six months
  • Resting hypotension (a resting systolic blood pressure of \<90 mm Hg) or hypertension (a resting blood pressure \> 170 mm Hg or a resting diastolic blood pressure of \>110 mm Hg)
  • NYHA Class III or IV heart failure
  • History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy
  • Serum creatinine \> 1.4 mg/dl
  • Triglycerides \> 400 at visit 1
  • Diabetic subjects with HbA1c \> 12%
  • Drug or alcohol abuse, or current intake of more than 14 standard drinks per week
  • Concurrent enrollment in another placebo-controlled trial
  • Presence of metal clips (i.e. bypass patients) or intracoronary stenting that preclude accurate measure of coronary calcification
  • Partial ileal bypass or known gastrointestinal disease limiting drug absorption
  • Current intake of garlic supplement or other prohibited drug (Appendix B)
  • Current tobacco use
  • Current use of anticoagulants (except for antiplatelet agents)
  • Chronic renal failure
  • Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2010

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT00860847

Start Date

May 1 2009

End Date

September 1 2010

Last Update

March 12 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Los Angeles Biomedical Research Institute

Torrance, California, United States, 90005